JAMES NATHANIEL MASON D.O.
Prescription History 1114362001
Internal Medicine - Hematology & Oncology in Ogden, UT

NPI Status: Active since May 06, 2013

Contact Information

4403 HARRISON BLVD STE 1670
OGDEN, UT
ZIP 84403
Phone: (801) 387-7150

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JAMES NATHANIEL MASON D.O., an active Hematology & Oncology specialist practicing in Ogden, UT. Our medical registry currently tracks 30 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,024 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydrocodone-Acetaminophen, which accounts for 137 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 43
30-Day Fills 57.0
Days Supply 1,710
UT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills35.2
Peer Average Days Supply943
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.5% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,011.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.53

State Avg Cost Per Claim

$25.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 720
UT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply660
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $346,641.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,443.42

State Avg Cost Per Claim

$12,722.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
UT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply709
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.5% more claims than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $409,365.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,405.02

State Avg Cost Per Claim

$13,910.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Deferasirox

Generic Formulation: DeferasiroxSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
UT State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills11.5
Peer Average Days Supply345
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.5% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,741.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$690.69

State Avg Cost Per Claim

$2,297.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

Therapeutic Applications

This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 46
30-Day Fills 50.5
Days Supply 1,189
UT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply376
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 76.9% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $539.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.72

State Avg Cost Per Claim

$15.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 85
30-Day Fills 121.0
Days Supply 3,585
UT State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills107.5
Peer Average Days Supply3,091
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.9% more claims than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,828.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$786.22

State Avg Cost Per Claim

$880.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 19.0
Days Supply 566
UT State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills130.5
Peer Average Days Supply3,829
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.9% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $162.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.53

State Avg Cost Per Claim

$26.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydrea

Generic Formulation: HydroxyureaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.3
Days Supply 319
UT State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$67.75

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 137
30-Day Fills 137.0
Days Supply 3,335
UT State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills60.4
Peer Average Days Supply1,202
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 128.3% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,065.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.97

State Avg Cost Per Claim

$20.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Hydromorphone Hcl

Generic Formulation: Hydromorphone HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 833
UT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.4
Peer Average Days Supply708
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $329.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.99

State Avg Cost Per Claim

$25.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Hydromorphone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 78
30-Day Fills 126.8
Days Supply 3,769
UT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply1,756
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 151.6% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,448.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.21

State Avg Cost Per Claim

$45.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,230
UT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.5
Peer Average Days Supply643
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 105.0% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,241.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$201.02

State Avg Cost Per Claim

$1,426.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 712
UT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.0
Peer Average Days Supply904
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $328,633.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,145.35

State Avg Cost Per Claim

$14,480.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
UT State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.0
Peer Average Days Supply441
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218,235.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,639.74

State Avg Cost Per Claim

$13,970.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 380
UT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.4
Peer Average Days Supply190
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $251.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.36

State Avg Cost Per Claim

$11.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
UT State Average Benchmarks
Peer Average Claims129.0
Peer Average 30-Day Fills319.2
Peer Average Days Supply9,485
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.9% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.52

State Avg Cost Per Claim

$19.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Methadone Hcl

Generic Formulation: Methadone HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,037
UT State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.4
Peer Average Days Supply806
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,412.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.24

State Avg Cost Per Claim

$20.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)

Therapeutic Applications

This medication is used to treat addiction to opioids (such as heroin) as part of an approved treatment program. Methadone belongs to a class of drugs known as opioid analgesics. It helps prevent withdrawal symptoms caused by stopping other opioids.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 504
UT State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills93.8
Peer Average Days Supply2,796
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.48

State Avg Cost Per Claim

$18.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Morphine Sulfate

Generic Formulation: Morphine SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 908
UT State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply668
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 39.3% more claims than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,563.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.08

State Avg Cost Per Claim

$38.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 983
UT State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills53.9
Peer Average Days Supply1,466
Conservative Utilization

This provider writes prescriptions for this formulation 35.8% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,424.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.89

State Avg Cost Per Claim

$40.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
UT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.0
Peer Average Days Supply556
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $146,806.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,346.05

State Avg Cost Per Claim

$11,387.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 48
30-Day Fills 48.0
Days Supply 1,090
UT State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills58.8
Peer Average Days Supply1,140
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,335.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.65

State Avg Cost Per Claim

$28.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 805
UT State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply756
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $602,051.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,760.40

State Avg Cost Per Claim

$20,031.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 15.0
Days Supply 190
UT State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills120.9
Peer Average Days Supply3,534
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.7% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $122.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.76

State Avg Cost Per Claim

$31.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Prednisone

Generic Formulation: PrednisoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 33
30-Day Fills 37.0
Days Supply 553
UT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills44.9
Peer Average Days Supply839
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $209.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.35

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 1,092
UT State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills49.3
Peer Average Days Supply1,329
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $680,448.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,447.41

State Avg Cost Per Claim

$17,981.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sprycel

Generic Formulation: DasatinibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
UT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.4
Peer Average Days Supply637
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $288,175.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,010.98

State Avg Cost Per Claim

$10,461.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 37
30-Day Fills 45.0
Days Supply 1,288
UT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply518
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 85.0% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,511.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.88

State Avg Cost Per Claim

$41.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Voriconazole

Generic Formulation: VoriconazoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
UT State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply544
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,680.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$223.34

State Avg Cost Per Claim

$518.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.

Therapeutic Applications

Voriconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 27
30-Day Fills 65.0
Days Supply 1,950
UT State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills70.1
Peer Average Days Supply2,036
Conservative Utilization

This provider writes prescriptions for this formulation 27.0% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35,465.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,313.53

State Avg Cost Per Claim

$974.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JAMES NATHANIEL MASON D.O. provides transparency into local medical care patterns within Ogden, UT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.